Structural diversity of selective COX-2 inhibitors

[1]  D. Riendeau,et al.  Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile. , 2002, Bioorganic & medicinal chemistry letters.

[2]  T. Schnitzer,et al.  Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. , 2002, Rheumatology.

[3]  L. Marnett,et al.  Isoform-selective interaction of cyclooxygenase-2 with indomethacin amides studied by real-time fluorescence, inhibition kinetics, and site-directed mutagenesis. , 2002, Biochemistry.

[4]  Philippe Chavatte,et al.  Investigations of new lead structures for the design of novel cyclooxygenase-2 inhibitors. , 2002, European journal of medicinal chemistry.

[5]  Lawrence J Marnett,et al.  Enantiospecific, selective cyclooxygenase-2 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[6]  K. Brune.  Next generation of everyday analgesics. , 2002, American journal of therapeutics.

[7]  Hiromasa Hashimoto,et al.  4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1). , 2002, Journal of medicinal chemistry.

[8]  Antonio Entrena,et al.  Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. , 2002, Journal of medicinal chemistry.

[9]  Lawrence J Marnett,et al.  Amide derivatives of meclofenamic acid as selective cyclooxygenase-2 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[10]  Hiromasa Hashimoto,et al.  4-Aryl/cycloalkyl-5-phenyloxazole derivatives as selective COX-2 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[11]  H. Kitasato,et al.  Cyclooxygenase‐1 and cyclooxygenase‐2 selectivity of non‐steroidal anti‐inflammatory drugs: investigation using human peripheral monocytes , 2001, The Journal of pharmacy and pharmacology.

[12]  R. Kurumbail,et al.  Cyclooxygenase enzymes: catalysis and inhibition. , 2001, Current opinion in structural biology.

[13]  D. Lesieur,et al.  Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis. , 2001, Journal of medicinal chemistry.

[14]  A. Weaver,et al.  Rofecoxib: clinical pharmacology and clinical experience. , 2001, Clinical therapeutics.

[15]  R. Kurumbail,et al.  A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. , 2001, The Biochemical journal.

[16]  R. D. Dyer,et al.  Slow-binding inhibition of human prostaglandin endoperoxide synthase-2 with darbufelone, an isoform-selective antiinflammatory di-tert-butyl phenol. , 2001, Biochemistry.

[17]  M. Michaelides,et al.  Thiazole analogues of the NSAID indomethacin as selective COX-2 inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[18]  Chun Xing Li,et al.  In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[19]  M. Noh,et al.  2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[20]  P. Loll,et al.  Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. , 2001, Biochemistry.

[21]  K. Sakane,et al.  The anti-inflammatory effect of FR188582, a highly selective inhibitor of cyclooxygenase-2, with an ulcerogenic sparing effect in rats. , 2001, Japanese journal of pharmacology.

[22]  R Gordon,et al.  Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. , 2001, The Journal of pharmacology and experimental therapeutics.

[23]  C. Almansa,et al.  Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines. , 2001, Journal of medicinal chemistry.

[24]  De Nanteuil G,et al.  1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite. , 2000, Journal of medicinal chemistry.

[25]  C. Koboldt,et al.  Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents. , 2000, Journal of medicinal chemistry.

[26]  L. Marnett,et al.  Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. , 2000, Journal of medicinal chemistry.

[27]  J. Carter,et al.  Inhibitors of cyclooxygenase-2: November 1999 - April 2000 , 2000 .

[28]  L. Marnett,et al.  Tyrosine-385 Is Critical for Acetylation of Cyclooxygenase-2 by Aspirin , 2000 .

[29]  L. Marnett,et al.  Fluorescence quenching analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectivity. , 2000, Biochemistry.

[30]  Lawrence J. Marnett,et al.  Structural insights into the stereochemistry of the cyclooxygenase reaction , 2000, Nature.

[31]  K. Yasui,et al.  Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. , 2000, Journal of medicinal chemistry.

[32]  C. Koboldt,et al.  N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. , 2000, Journal of medicinal chemistry.

[33]  R. Towart,et al.  Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: a novel compound exhibiting a marked preference for the human enzyme in intact cells , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[34]  R. S. Rogers,et al.  4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. , 2000, Journal of medicinal chemistry.

[35]  V. Segarra,et al.  Synthesis and biological evaluation of 3,4-diaryloxazolones: A new class of orally active cyclooxygenase-2 inhibitors. , 2000, Journal of medicinal chemistry.

[36]  L. Marnett,et al.  Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Riendeau,et al.  Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[38]  D. Riendeau,et al.  A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[39]  L. Marnett,et al.  Arachidonic Acid Oxygenation by COX-1 and COX-2 , 1999, The Journal of Biological Chemistry.

[40]  D. Riendeau,et al.  SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor. , 1999, Bioorganic & medicinal chemistry letters.

[41]  H Perrier,et al.  Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. , 1999, The Journal of pharmacology and experimental therapeutics.

[42]  M. Percival,et al.  The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. , 1999, Bioorganic & medicinal chemistry letters.

[43]  J. Vane,et al.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Riendeau,et al.  2-heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[45]  C. Koboldt,et al.  4,5‐Diaryloxazole inhibitors of cyclooxygenase‐2 (COX‐2) , 1999, Medicinal research reviews.

[46]  J. Gierse,et al.  Kinetic basis for selective inhibition of cyclo-oxygenases. , 1999, The Biochemical journal.

[47]  C. Koboldt,et al.  Design and synthesis of sulfonyl-substituted 4,5-diarylthiazoles as selective cyclooxygenase-2 inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[48]  C. Koboldt,et al.  Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[49]  R. D. Dyer,et al.  Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series. , 1999, Journal of medicinal chemistry.

[50]  R. Copeland,et al.  Terphenyl cyclooxygenase-2 (COX-2) inhibitors: optimization of the central ring and o-biphenyl analogs. , 1999, Bioorganic & medicinal chemistry letters.

[51]  R Gordon,et al.  2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. , 1999, Journal of medicinal chemistry.

[52]  C. Bayly,et al.  Structure-based design of COX-2 selectivity into flurbiprofen. , 1999, Bioorganic & medicinal chemistry letters.

[53]  D. Riendeau,et al.  Substituted heterocyclic analogs as selective COX-2 inhibitors in the flosulide class. , 1999, Bioorganic & medicinal chemistry letters.

[54]  P. Collins,et al.  Antiinflammatory 4,5-diarylimidazoles as selective cyclooxygenase inhibitors. , 1998, Bioorganic & medicinal chemistry letters.

[55]  L. Marnett,et al.  Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. , 1998, Journal of medicinal chemistry.

[56]  R Gordon,et al.  2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. , 1998, Bioorganic & medicinal chemistry letters.

[57]  S. Green,et al.  New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position. , 1998, Journal of medicinal chemistry.

[58]  L. Marnett,et al.  Aspirin-like molecules that covalently inactivate cyclooxygenase-2. , 1998, Science.

[59]  C. Cywin,et al.  Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2. , 1998, Bioorganic & medicinal chemistry letters.

[60]  S. Green,et al.  New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations of the dihydrobenzofuran ring. , 1998, Journal of medicinal chemistry.

[61]  R. Darolia,et al.  New cyclooxygenase-2/5-lipoxygenase inhibitors. 1. 7-tert-buty1-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: discovery and variation of the 5-keto substituent. , 1998, Journal of medicinal chemistry.

[62]  M. Tanaka,et al.  Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo , 1997, Inflammation Research.

[63]  M. Katori,et al.  Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. , 1997, Pharmacology.

[64]  K. Nakamura,et al.  Studies on anti-inflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives. , 1997, Chemical & pharmaceutical bulletin.

[65]  C. Koboldt,et al.  1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents. , 1997, Journal of medicinal chemistry.

[66]  C. Koboldt,et al.  1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. , 1997, Journal of medicinal chemistry.

[67]  J. Falgueyret,et al.  Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor , 1997, British journal of pharmacology.

[68]  R. S. Rogers,et al.  Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.

[69]  C. Cywin,et al.  Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. , 1997, Journal of medicinal chemistry.

[70]  R. Langenbach,et al.  Differential inhibition of murine prostaglandin synthase-1 and -2 by nonsteroidal anti-inflammatory drugs using exogenous and endogenous sources of arachidonic acid. , 1997, The Journal of pharmacology and experimental therapeutics.

[71]  P. Prasit,et al.  A new series of selective COX-2 inhibitors : 5,6-diarylthiazolo[3,2-b][1,2,4]triazoles , 1997 .

[72]  D. Riendeau,et al.  Synthesis and biological evaluation of 5,6-diarylimidazo[2.1-b]thiazole as selective COX-2 inhibitors , 1997 .

[73]  R. Copeland,et al.  Chemistry and pharmacokinetics of diarylthiophenes and terphenyls as selective COX-2 inhibitors , 1996 .

[74]  B. Kennedy,et al.  Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays. , 1996, Biochemical pharmacology.

[75]  D. Riendeau,et al.  NOVEL 1,2-DIARYLCYCLOBUTENES : SELECTIVE AND ORALLY ACTIVE COX-2 INHIBITORS , 1996 .

[76]  J. Chow,et al.  Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 , 1996, Nature Structural Biology.

[77]  Jilly F. Evans,et al.  Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. , 1996, Biochemical pharmacology.

[78]  L. Marnett,et al.  Kinetics of the interaction of nonsteroidal antiinflammatory drugs with prostaglandin endoperoxide synthase-1 studied by limited proteolysis. , 1996, Biochemistry.

[79]  P. Loll,et al.  Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. , 1996, Biochemistry.

[80]  K. Seibert,et al.  Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. , 1996, Gastroenterology clinics of North America.

[81]  C. Koboldt,et al.  Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. , 1996, Journal of medicinal chemistry.

[82]  C. Bayly,et al.  From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors , 1996 .

[83]  C. Koboldt,et al.  Diarylspiro[2.4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationships. , 1996, Journal of medicinal chemistry.

[84]  C. Chan,et al.  Cyclooxygenase-2 inhibitors. Synthesis and pharmacological activities of 5-methanesulfonamido-1-indanone derivatives. , 1995, Journal of medicinal chemistry.

[85]  R. S. Rogers,et al.  3,4-diarylthiophenes are selective COX-2 inhibitors , 1995 .

[86]  C. Patrono,et al.  Effects of the novel anti‐inflammatory compounds, N‐[2‐(cyclohexyloxy)‐4‐nitrophenyl] methanesulphonamide (NS‐398) and 5‐methanesulphonamido‐6‐(2, 4‐difluorothiophenyl)‐1‐indanone (L‐745, 337), on the cyclo‐oxygenase activity of human blood prostaglandin endoperoxide synthases , 1995, British journal of pharmacology.

[87]  C. Koboldt,et al.  1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. , 1995, Journal of medicinal chemistry.

[88]  G. Norbiato,et al.  Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. , 1995, Arzneimittel-Forschung.

[89]  R. Copeland,et al.  Antiinflammatory 4,5-diarylpyrroles. 2. Activity as a function of cyclooxygenase-2 inhibition. , 1995, Journal of medicinal chemistry.

[90]  P. Prasit,et al.  Synthesis and biological evaluation of 2,3-diarylthiophenes as selective Cox-2 and Cox-1 inhibitors , 1995 .

[91]  K. Glaser,et al.  Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. , 1995, European journal of pharmacology.

[92]  M. Trevethick,et al.  Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDS and Cox 2 inhibitors , 1995, Inflammation Research.

[93]  C. Koboldt,et al.  SELECTIVE CYCLOOXYGENASE INHIBITORS : NOVEL 4-SPIRO 1,2-DIARYLCYCLOPENTENES ARE POTENT AND ORALLY ACTIVE COX-2 INHIBITORS , 1995 .

[94]  K. Seibert,et al.  Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[95]  P. Hsyu,et al.  Pharmacokinetics and cyclooxygenase inhibition of itazigrel in normal volunteers after single oral doses. , 1994, Journal of pharmaceutical sciences.

[96]  S. Iacobelli,et al.  Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. , 1994, The Journal of pharmacology and experimental therapeutics.

[97]  H. Chan,et al.  Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. , 1994, Biochimica et biophysica acta.

[98]  C. Koboldt,et al.  Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. , 1994, Journal of medicinal chemistry.

[99]  R. Copeland,et al.  Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[100]  D. Breuer,et al.  Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. , 1994, The Journal of pharmacology and experimental therapeutics.

[101]  C. Ji,et al.  Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. , 1994, The Journal of biological chemistry.

[102]  A. Tanaka,et al.  Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. , 1994, Journal of medicinal chemistry.

[103]  K. Seibert,et al.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[104]  B. Jaffee,et al.  Antiinflammatory 4,5-diarylpyrroles: synthesis and QSAR. , 1994, Journal of medicinal chemistry.

[105]  P. Loll,et al.  The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 , 1994, Nature.

[106]  C. Thiemermann,et al.  Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[107]  R. D. Dyer,et al.  Design of 5-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazoles, -1,3,4-oxadiazoles, and -1,2,4-triazoles as orally-active, nonulcerogenic antiinflammatory agents. , 1993, Journal of medicinal chemistry.

[108]  D. Dewitt,et al.  Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. , 1993, The Journal of biological chemistry.

[109]  K. Nakamura,et al.  Studies on antiinflammatory agents. I. Synthesis and pharmacological properties of 2'-phenoxymethanesulfonanilide derivatives. , 1992, Chemical & pharmaceutical bulletin.

[110]  K. Tanaka,et al.  Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne. 1st communication: antiinflammatory, analgesic and other related properties. , 1992, Arzneimittel-Forschung.

[111]  N. Ackerman,et al.  Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. , 1990, The Journal of pharmacology and experimental therapeutics.

[112]  C. Metzler,et al.  The Effect of Itazigrel and Aspirin on the Mucosa of the Esophagus, Stomach, and Duodenum of Normal Subjects , 1987, Journal of clinical pharmacology.

[113]  T. Sharpe,et al.  Preparation and antiarthritic and analgesic activity of 4,5-diaryl-2-(substituted thio)-1H-imidazoles and their sulfoxides and sulfones. , 1985, Journal of medicinal chemistry.

[114]  G. Moore,et al.  4-nitro-2-phenoxymethanesulfonanilide (R-805): a chemically novel anti-inflammatory agent. , 1976, Archives internationales de pharmacodynamie et de therapie.

[115]  L. Rome,et al.  Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[116]  G J Roth,et al.  Acetylation of prostaglandin synthase by aspirin. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[117]  M. I. Gluckman,et al.  Anti-inflammatory properties of 4,5-diphenyl-2-oxazolepropionic acid (oxaprozin) , 1974, Agents and Actions.

[118]  J. Vane,et al.  Effects of anti-inflammatory drugs on prostaglandin biosynthesis. , 1972, Nature: New biology.

[119]  A. B. Wilson,et al.  Diaryloxazole and Diarylthiazolealkanoic Acids: Two Novel Series of Non-steroidal Anti-inflammatory Agents , 1968, Nature.

[120]  E. Glenn,et al.  Synthesis and antiinflammatory activity of 2,3-bis(p-methoxyphenyl)indole and related compounds. , 1966, Journal of medicinal chemistry.

[121]  A Ward,et al.  Pentoxifylline , 1987, Drugs.

[122]  A. Schweizer,et al.  The pharmacological profile of CGP 28238, a highly potent anti-inflammatory compound , 2005, Agents and Actions.

[123]  R. Caprioli,et al.  Functional analysis of the molecular determinants of cyclooxygenase-2 acetylation by 2-acetoxyphenylhept-2-ynyl sulfide. , 2003, Archives of biochemistry and biophysics.

[124]  F. Mckenna,et al.  Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis. , 2002, Clinical and experimental rheumatology.

[125]  L. Sorbera,et al.  Treatment of heart failure vasopressin V2 antagonist , 2002 .

[126]  Nikolai Kuhnert.  Hundert Jahre Aspirin® ‐ Die Geschichte des wohl erfolgreichsten Medikaments des letzten Jahrhunderts , 2000 .

[127]  J. Talley,et al.  Selective inhibitors of cyclooxygenase-2 (COX-2). , 1999, Progress in medicinal chemistry.

[128]  P. Prasit,et al.  From indomethacin to a selective COX-2 inhibitor. Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors. , 1997, Advances in experimental medicine and biology.

[129]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[130]  S. Higuchi,et al.  NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. , 1994, Prostaglandins.

[131]  M. Whitehouse,et al.  Antiinflammatory agents : chemistry and pharmacology , 1974 .

[132]  D. Kvam,et al.  Antiinflammatory agents. I. 3-Benzoylfluoroalkanesulfonamides. , 1970, Journal of medicinal chemistry.

[133]  R. Johnson,et al.  Correlation of serum indoxole [2,3-bis(p-methoxyphenyl)-indole] levels with biologic activity. , 1967, The Journal of pharmacology and experimental therapeutics.

[134]  M. Myers,et al.  The pharmacology of 2,3-bis-(p-methoxyphenyl)-indole (indoxole). , 1967, The Journal of pharmacology and experimental therapeutics.

[135]  Frey Hh,et al.  Contributions to the evaluation of antiphlogistic test results. 2. Comparison of the effects of phenylbutazone with various models of inflammation , 1966 .